Michael Dinerman, M.D., served as the Chief Operating Officer of Viking Therapeutics from June 2014 until his resignation in September 2015. During his tenure, he was pivotal in steering the company through its initial public offering and advancing key research...

Michael Dinerman, M.D., served as the Chief Operating Officer of Viking Therapeutics from June 2014 until his resignation in September 2015. During his tenure, he was pivotal in steering the company through its initial public offering and advancing key research studies. Despite leaving the company, Dr. Dinerman's influence remains through the momentum he helped generate. Post-resignation, he received a severance package worth about $74,500, demonstrating the company's appreciation for his prior contributions. His compensation history reveals an interesting phase where he held significant stock options, but those were canceled upon his departure. Beyond numbers, what stands out about Dr. Dinerman is his strategic vision during a transformative period for Viking Therapeutics. After his resignation, he engaged in notable insider trading activities, demonstrating confidence in Viking's potential, with transaction values peaking over $5 million in mid-2019 and fluctuating significantly over the years. This pattern shows that despite leaving his official role, he closely monitored the company's performance, indicating a lasting commitment to its success.